Can we exploit the molecular heterogeneity of aggressive B cell lymphomas into effective new therapies

Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma, with an estimated incidence of>25,000 cases in 2016, representing roughly one-quarter of all newly diagnosed mature lymphoid neoplasms.1 High grade B cell lymphoma (HGBL) is a less frequently-occurring subtype of non-Hodgkin lymphoma, and was first identified in the 2016 revision of the World Health Organization classification of lymphoid neoplasms, replacing the former category of B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research